The world's most expensive hedge fund, which charges 50% performance fees compared with an average 20%, is being sued by a Canadian pharmaceutical company for alleged stock market manipulation.

Biovail has filed a lawsuit seeking up to $13.8bn €11.7bn) from 22 defendants including SAC Capital, which manages $7bn.